Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma

Inclusion criteria

• ✓. Blood routine: WBC ≥ 3500 / mm3 (3.5 \* 109 / L); Neutrophil count (ANC) ≥ 180 / mm3 (1.8 \* 109 / L); Platelet count ≥ 125000 / mm3 (125 \* 109 / L); Hemoglobin: male ≥ 13g / dl (130g / L); female ≥ 11.5g/dl (115g / L);
• ✓. Blood biochemistry: Total bilirubin ≤ 1.5 \* ULN (total bilirubin of Gilbert syndrome \<3.0mg / dL); Aspartate aminotransferase (AST / SGOT), alanine aminotransferase (ALT / SGPT) and alkaline phosphatase ≤ 2.5 \* ULN; Creatinine ≤1.5 \* normal upper limit (ULN);
• ✓. Coagulation function: The international standard ratio (INR) is less than 1.5 (or the INR value is 2-3 when patients take farwarin stably for a long time), and prothrombin time (PT) is less than 1.5 \* ULN;
• ✓. Lung function test: Lung diffusion (DLCO) ≥ 70% predicted OR; DLCO \<70% but ≥ 55%, and the maximum oxygen uptake (VO2 max) ≥ 10L / min / kg (by cardiopulmonary assessment) or 6 minutes walking test ≥ 500 meters; Patients with DLCO \<55% were not included in this study; Pulse oximetry during rest and walking ≥ 92%;
• ✓. Heart function test: Baseline ECG showed no prolonged PR interval or atrioventricular block;